Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2008

View Archived Issues

Studies show analgesic efficacy of ARRY-797 in postsurgical dental pain

Pooled GOUT 1 and GOUT 2 data detail effects of pegloticase

Recent University of Aberdeen patent discloses novel agents for bone disorders

New therapeutic agents for neurological disorders reported in recent patent literature

Thalidomide not effective in treating amyotrophic lateral sclerosis

Antimicrobial activity of host defense peptide mimetics described

NIH awards SBIR grant to BioSante to develop pulmonary delivery of IFN-alpha

Boehringer Ingelheim commences phase III pivitol program for Vargatef

DSMC authorizes Bioniche to continue phase III Urocadin trial in bladder cancer

Innocoll receives FDA fast track designation for Gentamicin Surgical Implant

Relistor approved in Australia for opioid-induced constipation

Life Science Pharmaceuticals enters into agreement with Abbott for Antibody 806

Eli Lilly and United Therapeutics enter license and supply agreement for PAH

SciClone reaches agreement with FDA on SPA for phase III thymalfasin trial

Solvay discontinues R&D activities of antiobesity compound SLV-319

Theratechnologies completes treatment of patients in extension phase of tesamorelin trial

Biotie acquires Elbion NV's subsidiary Elbion GmbH

Proteome Systems changes name to Tyrian Diagnostics

Affymax completes enrollment in EMERALD 2 phase III clinical trial of Hematide

Serenity initiates phase II clinical study of intranasal drug for urology indication

Novel dopamine D3 receptor agonists and antagonists described by Pfizer

Preclinical activity of PF-03800130 shows benefit in bipolar disorder-associated mood symptoms

Phase II results with rivaroxaban in acute coronary syndromes reported

New compounds for hypogonadism described in recent GSK patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...